Zentiva Completes Acquisition of APONTIS PHARMA AG Voting Rights with Significant Stake

Zentiva's Strategic Acquisition of APONTIS PHARMA

In a significant development for the pharmaceutical landscape in Europe, Zentiva AG, a distinguished subsidiary of Zentiva Pharma GmbH based in Frankfurt, has successfully achieved approximately 83.57% of APONTIS PHARMA AG's share capital and 85.27% of its voting rights. This acquisition, part of a voluntary public purchase offering, underscores Zentiva's strategic goals to broaden its influence and enhance its service delivery of quality, affordable medicines.

The acceptance period for this offer concluded on November 21, 2024, and Steffen Saltofte, Zentiva’s CEO, expressed satisfaction regarding this progress. He stated, "We are pleased with the success of our public purchase offer. This milestone marks a significant step forward in our journey to expand our reach and enhance our ability to deliver high-quality, affordable medicines to the people who depend on them every day."

With this acquisition, Zentiva aims to integrate its strengths with APONTIS PHARMA’s innovative product lines, which focus primarily on single pill combinations, an area that has proven effective in improving patient adherence to medication regimens. Zentiva plans to leverage APONTIS's expertise in combination therapies to strengthen its portfolio further, responding to the growing demand for solutions that support patients managing chronic conditions.

The completion of the transaction remains contingent upon foreign direct investment control clearance in Germany, with settlement anticipated by the end of December 2024 or in the first quarter of 2025. This integration is set to optimize operational synergies and introduce a collective approach to delivering patient-centric solutions in vital therapeutic areas, including cardiology, oncology, and more.

Founded on the principle of providing accessible healthcare, Zentiva serves over 100 million people across Europe. The company operates four wholly-owned manufacturing facilities and a robust network of external partners, ensuring consistent supply security. It has strategically positioned itself in essential therapeutic domains—growing its portfolio, particularly in self-care products, over the next five years.

Regarding APONTIS PHARMA, established in 2013, the company is a leader in single-pill therapies in Germany. Its innovative products simplify complex treatment regimens, offering a more manageable approach for patients on multiple medications. APONTIS PHARMA has focused heavily on treating cardiovascular diseases, enhancing both treatment adherence and patient outcomes. Their single-pill combinations, which integrate multiple active ingredients into a single daily dosage, exemplify the modern approach to pharmaceutical care—reducing complications, improving efficiency, and lowering costs associated with treatment.

The merger not only enhances Zentiva’s reach within European markets but represents a deliberate move towards shaping the future of medication adherence solutions. As both companies align under a united ownership structure, they anticipate significant strides in research, product development, and market innovation. This acquisition reinforces their commitment to improving health and wellbeing across generations.

Zentiva is dedicated to creating a workplace where every employee feels valued, encouraging collaboration among its team of nearly 5,000 professionals. Ensuring a diverse and inclusive work environment complements their business strategy, fostering creativity and enhancing their ability to respond effectively to the dynamic landscape of healthcare.

For further information on Zentiva, you can visit their websites www.zentiva.com and www.zentiva.de. Additionally, more about APONTIS PHARMA can be found at www.apontis-pharma.de. This acquisition is poised to redefine the dimensions of patient care in the pharmaceutical industry, setting a benchmark for quality and affordability.